Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea
· Delayed Price · Currency is KRW 6,600.00
-430.00 (-6.12%)
Mar 9, 2026, 3:30 PM KST
Oncocross Revenue
Oncocross had revenue of 29.18M KRW in the quarter ending September 30, 2025, a decrease of -84.03%. This brings the company's revenue in the last twelve months to 884.68M, up 103.05% year-over-year. In the year 2024, Oncocross had annual revenue of 1.07B with 1,071.49% growth.
Revenue (ttm)
884.68M
Revenue Growth
+103.05%
P/S Ratio
90.99
Revenue / Employee
n/a
Employees
n/a
Market Cap
80.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.07B | 980.68M | 1,071.49% |
| Dec 31, 2023 | 91.52M | -58.72M | -39.08% |
| Dec 31, 2022 | 150.25M | 50.25M | 50.25% |
| Dec 31, 2021 | 100.00M | 10.00M | 11.11% |
| Dec 31, 2020 | 90.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeneOne Life Science | 30.90B |
| Amicogen | 87.97B |
| IMB Dx | 4.26B |
| ORIENT BIO | 59.09B |
| CG Invites | 18.12B |
| ENCell | 5.91B |
| Macrogen | 179.98B |
| Vaxcell-Bio Therapeutics | 1.90B |